1. P18-13 LB. Immunogenicity of an autologous dendritic cell anti-HIV therapy in HIV-1 infected individuals
- Author
-
Z Coutsinos, B. Yassine Diab, Claire Landry, Rafik-Pierre Sekaly, D Sauvé, V Hébert, Jean-Pierre Routy, Dominic Gagnon, D Healey, Charles Nicolette, C Hébert-Benoît, R Jain, Irina Y. Tcherepanova, and M. R. Boulassel
- Subjects
CD40 ,biology ,business.industry ,viruses ,medicine.medical_treatment ,Immunogenicity ,virus diseases ,Drug holiday ,Immunotherapy ,Dendritic cell ,Infectious Diseases ,Antigen ,Virology ,Poster Presentation ,Immunology ,medicine ,biology.protein ,Anti-HIV Therapy ,Antibody ,business - Abstract
Background The immunogenicity of an autologous dendritic cell (DC) anti-HIV therapy, AGS-004, was evaluated in a multicenter Phase 2 trial. The treatment regiment consisted of four intradermal doses, administered monthly in combination with anti-retroviral therapy (ART) followed by a well-controlled structured treatment interruption (STI). The immunotherapy consisted of monocyte-derived DC co-electroporated with CD40L in vitro transcribed (IVT) RNA along with amplified IVT RNA encoding for 4 HIV-1 antigens (GAG, NEF, REV and VPR).
- Published
- 2009